Abstract. Type 13 transforming growth factor (TGFI3) has been shown to be both a positive and negative regulator of cellular proliferation and differentiation. The effects of TGFI3 also are cell-type specific and appear to be modulated by other growth factors. In the present study, we examined the potential of TGFI3 for control of myogenic differentiation. In mouse C-2 myoblasts, TGFfl inhibited fusion and prevented expression of the muscle-specific gene products, creatine kinase and acetylcholine receptor. Differentiation of the nonfusing muscle cell line, BC3H1, was also inhibited by TGFI3 in a dose-dependent manner (IDs0 ~0.5 ng/ml). TGFI3 was not mitogenic for either muscle cell line, indicating that its inhibitory effects do not require cell proliferation. Inhibition of differentiation required the continual presence of TGFI3 in the culture media. Removal of TGFI3 led to rapid appearance of muscle proteins, which indicates that intracellular signals generated by TGFfl are highly transient and require continuous occupancy of the TGFI~ receptor. Northern blot hybridization analysis using a muscle creatine kinase cDNA probe indicated that TGFI3 inhibited differentiation at the level of muscle-specific mRNA accumulation. These results provide the first demonstration that TGFI3 is a potent regulator of myogenic differentiation and suggest that TGFI3 may play an important role in the control of tissue-specific gene expression during development.
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T
YPE I~ transforming growth factor (TGFI3) j is a polypeptide homodimer of total Mr 25,000 that is abundant in platelets and is also present in a wide variety of tissues as well as in transformed cells (1, 2, 19, 20, 31, 37) . TGFfl was first discovered by its ability to induce transformation in normal cells (31). The cellular actions of TGFI3 are highly cell type specific and have been reported to be modulated by other growth factors present in serum (20, 21, 31, 32, 37) . The pleiotropic effects of TGFI3 include induction of anchorage-independent growth in mesenchymal cells (32) , inhibition of adipocyte differentiation (11) , induction of collagen and fibronectin synthesis (12) , inhibition of epithelial cell proliferation, and stimulation of epithelial cell differentiation (22) . In aortic smooth muscle cells, TGFI3 also acts by inhibiting proliferation of subconfluent monolayer cultures, whereas it synergizes with mitogens to stimulate growth in soft agar (2) . The physiological role of this growth factor in the control of cellular proliferation and differentiation as well as the mechanisms whereby TGFI3 elicits its cellular responses remain to be determined.
The process of myogenesis involves withdrawal of proliferating myoblasts out of the cell cycle, their subsequent fusion to form multi-nucleated myotubes, and the coordinate induc-1. Abbreviations used in this paper: ACh, acetylcholine; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MCK, muscle isoenzyme of creatine kinase; TGF13, type 13 transforming growth factor. tion of a battery of muscle-specific gene products (23) (24) (25) . Because activation of muscle-specific gene expression is coupled to cell cycle withdrawal rather than to fusion, a great deal of interest has focused on the role of growth factors in the control of muscle differentiation (4, 6, 7, 9, 10, 13, 14, 16-18, 24, 25, 27-30, 35) . The majority of studies on regulation of myogenesis by mitogens have used fetal calf serum (FCS) as a crude source of mitogenic activity. With the exception of fibroblast growth factor, which has been shown to inhibit muscle differentiation in a manner similar to serum (9, 10, 13, 14, 17, 18, 35) , little is known of the identities or mechanisms of action of growth factors that regulate myogenesis.
Because of the diverse actions of TGF~, we examined the possible involvement of this growth factor in the control of myoblast proliferation and differentiation, using the C-2 and BC3H1 cell lines. These cell lines have been shown to exhibit properties of skeletal muscle and smooth muscle, respectively, after differentiation in media without mitogens (27-29, 34, 36, 38) . In fusion-promoting media containing TGFI3, C-2 cells withdrew from the cell cycle but failed to fuse or differentiate as defined by expression of muscle creatine kinase and nicotinic acetylcholine (ACh) receptor. Similarly, in BC3H1 cells, TGFI~ delayed the onset of differentiation and inhibited muscle-specific mRNA accumulation. TGFfl was not mitogenic for either cell line, which indicates that its inhibitory effects on differentiation were not a secondary consequence of cell proliferation. These data demonstrate that TGFI3 is a unique regulator of myogenic differentiation and suggest that TGFI3 may play an important role in the control of tissue-specific gene expression during early development.
Materials and Methods

Cell Culture
The BC3H1 mouse muscle cell line (34) was grown in DME containing 20% FCS (Hazelton Research Products, Denver, PA) as described previously (27) . To initiate differentiation, media containing 20% serum was removed and replaced with media containing 0.5 % serum.
The C-2 mouse muscle cell line (38) was grown in DME containing 20% FCS, 100 t~g/ml L-glutamine, penicillin (100 U/ml), and streptomycin (100 ~tg/ml). To initiate fusion, cultures were transferred to DME containing 10 gg/ml insulin, 5 gg/ml transferrin.
TGFI3 (R & D Products, Minneapolis, MN) was resuspended in sterile 4 mM HCI at 10 gg/ml and stored at -20°C. Cell numbers were determined using a Coulter Counter (Coulter Electronics Inc., Hialeah, FL) and were confirmed with a hemocytometer. To determine the extent of fusion, nuclei were counted visually in five randomly selected fields at a magnification of 100. Cells containing >2 nuclei were considered to be fused. For metabolic labeling of proteins, cultures were incubated for 2 h with L-[35S]methionine (New England Nuclear, Boston, MA; ,M,000 Ci/mmol) at 100 ixCi/ml in DME without methionine and containing 0.5 % FCS dialyzed against PBS (140 mM NaCI, 10 mM Na2HPO4, pH 7.2). At the end of the labeling period, extracts were prepared as described previously (27) .
Creatine Kinase and ACh Receptor Assays
Creatine kinase was assayed as described previously (27) . ACh receptors were assayed by specific binding of [125I]a-bongarotoxin to cell monolayers as described (28, 29) .
Preparation of Total Cellular RNA
Total cellular RNA was prepared from cultures according to a modification of the 8 M guanidine HC1 procedure as described previously (27) .
Labeling cDNA Probes
To quantitate steady-state levels of muscle isoenzyme of creatine kinase (MCK) mRNA, a SmaI-EcoRI restriction fragment was isolated from plasmid R21 containing an insert homologous to canine MCK mRNA (33) . Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was measured using a 1,650-base pair HhaI restriction fragment isolated from a chicken GAPDH cDNA clone, pGAD-28 (5). Inserts were labeled with 32p to a specific activity of 1-5 x 109 cpm/~tg as described by Feinberg and Vogelstein (8) .
Northern Blot Hybridization
Formaldehyde-agamse gel electmphoresis of RNA and Northern blot hybridization were performed as described previously (35). Blots were exposed to Kodak XAR film at -70°C with DuPont Lightning-Plus intensifying screens (DuPont Co., Wilmington, DE). For quantitation of mRNAs, films were exposed for periods during which band intensity was linear with respect to time. Films were then scanned with a densitometer and mRNA abundance was determined from the area under the peak corresponding to individual mRNAs. Hybridization of cDNA probes to total cellular RNA was linear with respect to RNA concentration.
IEF/SDS PAGE
Two-dimensional gel electrophoresis of [35S]methionine-labeled proteins was performed as described by O'Farrell (26) . After staining and destaining, gels were treated with EN3HANCE (New England Nuclear) according to manufacturer's instructions.
Results
TGF~ Inhibits Myoblast Fusion and Appearance of Muscle-specific Proteins
C-2 cells proliferate rapidly in media with 20% FCS and do not express the muscle phenotype. Transfer to media containing insulin and transferrin (fusion-promoting media) results in withdrawal of cells from the cell cycle within ",24 h followed by fusion to form multinucleated myotubes over a period of ",3 d (Fig. 1) . The process of fusion is accompanied by induction of creatine kinase and the ACh receptor (Fig. 2) .
To examine the possibility that TGFI3 might influence myogenic differentiation, proliferating, undifferentiated C-2 cells were exposed to fusion-promoting media with TGFI3 (5 ng/ml). In the presence of TGFI~, C-2 cells withdrew from the cell cycle and achieved the same cell density as untreated cells (Fig. 2) . However, cells treated with TGFI3 retained the bipolar morphology, characteristic of proliferating cells, and failed to fuse at the normal rate ( Figs. 1 and 2 ). TGFI3 also delayed induction of ACh receptor and creatine kinase for •48 h, after which, cultures began to fuse and differentiate .
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>, Figure 2 . Effects on TGFI~ on differentiation of C-2 cells. C-2 cells were cultured in DME with 20% serum as described in Fig. 1 . On each day, nuclei per dish (A) were counted, the extent of fusion (B) was determined, and ACh receptors (C) and creatine kinase activity (D) were measured. On day 3, cultures were transferred to fusion-promoting media with or without TGFI3 (5 ng/ml). On day 7, TGFI3 was added to myotubes and was removed from TGFI3-treated cultures. Fresh TGFI3 was added every 48 h to TGFI3-treated cultures. Note that TGFI3 suppresses differentiation of mononucleated myoblasts and that differentiation proceeds at a normal rate after its removal. However, exposure of myotubes to TGFI3 has little or no effect on differentiation. (Fig. 2) .
We also examined the potential ability of TGFI3 to repress expression of muscle-specific gene products in myotubes. As shown in Fig. 2 , exposure of myotubes to TGF[~ had little or no effect on expression of ACh receptor. In separate experiments, it was found that creatine kinase also continued to be induced after the addition of TGFI3 to myotubes (Table I) .
Together, these results demonstrate that TGF[~ inhibits differentiation of C-2 cells through a reversible mechanism that requires its continual presence in culture media. After fusion, C-2 cells become committed to terminal differentiation and lose their sensitivity to the inhibitory effects of TGFI3. Inhibition of differentiation by TGF[~ was not a secondary consequence of cell proliferation because TGF[3 exhibited no mitogenic activity for C-2 cells (Fig. 2 A) .
Because of the pleiotropic actions of TGF[3 on different cell types, we were interested in whether the inhibitory effects of this growth factor on myogenic differentiation were common to other muscle cell lines. BC3H1 cells are a nonfusing cell line that has been shown to exhibit smooth muscle characteristics after differentiation in media containing 0.5 % serum (34, 36) . The effects of TGFI3 on proliferation and Conditions are identical to those on days 6 and 7 in Fig. 2 . Undifferentiated C-2 cells were transferred to fusion promoting media for 3 d and creatine kinase activity was determined. Half of the remaining cultures were then exposed to TGFI3 (5 ng/ml) for 1 d and creatine kinase activity was determined in the treated and untreated cultures. Note that TGFI3 fails to block induction of creatine kinase in myotubes.
differentiation of BC3H1 cells are shown in Fig. 3 . Exposure of proliferating undifferentiated BC3H1 cells to 0.5 % serum containing TGFI3 (5 ng/ml) resulted in withdrawal of cells out of the cell cycle within 24 h. However, in contrast to control cultures that acquire an elongated refractile appearance after growth arrest (27, 34) , TGF~treated cultures maintained a flattened stellate morphology characteristic of undifferentiated cells (data not shown). Cultures treated with TGF[3 also failed to differentiate at a normal rate as defined by expression of ACh receptor and creatine kinase (Fig.  3) . While TGFI~ clearly inhibited differentiation of BC3H1 cells, its effects were more complete in C-2 cells. The incomplete inhibition of differentiation of BC3H1 cells was probably due, at least in part, to depletion of TGFI3 from the media, since daily additions of TGFI3 caused greater (although not total) repression (data not shown). As we observed for C-2 cells, inhibition of differentiation by TGFI3 was rapidly reversible after its removal from the culture media. To determine whether TGFI3 could inhibit expression of muscle-specific gene products in differentiated cells, quiescent differentiated cultures were exposed to TGF[3. As shown in Fig. 3 , TGFI3 caused a block in creatine kinase induction and a loss of ACh receptors from the cell surface at a rate equivalent to that reported previously for cultures exposed to media with 20% serum (28, 29) . Thus, unlike C-2 myotubes which were refractory to "rGFI3, BC3H1 cells remained sensitive to the inhibitory effects of TGFI3 after differentiation.
The dose dependence for repression of differentiation by TGFI3 was examined by transferring proliferating undifferentiated BC3H1 cells to media containing 0.5 % serum with or without TGFIt After 48 h, ACh receptors and creatine kinase activity were measured. As shown in Fig. 4 , inhibition of differentiation could be observed at a TGFI3 concentration as low as 0.20 ng/ml. Half-maximal repression occurred at '~,0.5 ng/ml and maximal repression at '~1 ng/ml.
Together, the data in Figs. 1-4 demonstrate that TGFI3 inhibits expression of muscle-specific proteins in both C-2 and BC3HI cells through a highly transient mechanism that is independent of cell proliferation. Inhibition of differentiation is not a general response to all growth factors because neither epidermal or platelet-derived growth factor had an apparent effect on expression of creatine kinase or ACh receptor (our unpublished results). Figure 3 . Effects of TGFI~ on differentiation of BC3H1 cells. BC3HI cells were cultured in DME with 20% serum as described in Materials and Methods. On each day, cells per dish (A) were counted and ACh receptors (B) and creatine kinase activity (C) were measured. On day 3, cultures were transferred to DME with 0.5% serum with or without TGFfl (5 ng/ml). On day 7, TGFl~-treated cultures were transferred to fresh media without TGFI3 and quiescent differentiated cultures were exposed to TGFI~ (5 ng/ml). Fresh TGFI3 was added every 48 h to TGFl~-treated cultures. Note that TGFI~ inhibits appearance of muscle-specific proteins and that after its removal, differentiation proceeds normally. Addition of TGFI~ to quiescent differentiated cells also blocks accumulation of muscle proteins. 
TGFI3 Inhibits Accumulation of M C K mRNA
Previously we reported that differentiation of BC3H1 cells was accompanied by accumulation of MCK mRNA. Exposure of quiescent differentiated cells to media with 20 % serum or fibroblast growth factor resulted in a decline in abundance of MCK mRNA (35). To determine whether TGFI3 inhibited differentiation through a mechanism similar to serum and fibroblast growth factor, steady-state levels of MCK mRNA were quantitated by Northern blot hybridization analysis. As shown in Fig. 5 , exposure of quiescent differentiated cells to TGFI3 or to media with 20% serum resulted in a dramatic decrease in the steady-state level of MCK mRNA. This effect of TGFfl was specific for MCK mRNA as demonstrated by the lack of an effect on the steadystate level of GAPDH mRNA. Steady-state levels of GAPDH mRNA do not change in response to proliferation or differen- Figure 5 . TGFI3 specifically inhibits expression of MCK mRNA in BC3HI cells. BC3H1 cells were allowed to differentiate for 4 d in media with 0.5% serum. Cultures were then exposed to media containing 0.5 % serum with or without TGFI3 (5 ng/ml) or 20% serum, as specified. After 17 h, RNA was isolated and the relative abundance of MCK mRNA and GAPDH mRNA was determined by Northern blot hybridization. Note that TGFI3 and 20% serum both cause a loss of MCK mRNA but have no effect on GAPDH mRNA. The position of 18 S ribosomal RNA is indicated. tiation of BC3H1 cells (35). These data demonstrate that TGFI3 can regulate myogenesis by specifically repressing muscle-specific mRNA accumulation.
TGF~ Regulates Expression of a Variety of Proteins in BC3H! Cells
Because of the dramatic effects of TGFI3 on creatine kinase and ACh receptor, we were interested in determining whether expression of other gene products also might be inhibited by TGFI3. To analyze the effects of TGFI3 on the pattern of protein synthesis, quiescent differentiated BCaH1 cells were exposed to TGFI3 for 28 h. Cultures were then labeled for 2 h with [35S]methionine and labeled polypeptides were separated by two-dimensional gel electrophoresis. As shown in Fig. 6 , 10 proteins can be observed to decrease in abundance and '~6 proteins to increase in abundance after treatment of quiescent differentiated cells with TGFI3. Because only relatively abundant polypeptides are visualized on these gels, these represent minimum estimates of the total number of gene products whose expression is regulated by TGFI~ in these cells. The identities of the proteins that are down regulated by TGFI3 are currently unknown, but it seems likely some may represent muscle-specific gene products since they are regulated in parallel with creatine kinase and ACh receptor.
Discussion
During myogenesis, myoblasts cease dividing before activation of muscle-specific genes (4, 6, 7, 9, 10, 13, 14, 16-18, 24, 25, 27-30, 35) . While serum components clearly play a key role controlling the onset of myogenic differentiation, the identities and mechanisms of action of the specific growth factors that regulate this process are only beginning to be understood. The characteristics of the quiescent state that allow muscle-specific gene expression also remain unclear.
The results of the present study demonstrate that TGFI3 is a potent regulator of myogenesis that specifically inhibits one or more steps leading to activation of muscle-specific gene expression in both smooth muscle-like and skeletal muscle cells. Because TGFI3 was not mitogenic for either muscle cell type, this growth factor appears to interfere directly with the differentiation program and does not seem to influence differentiation as a secondary consequence of cell proliferation. In this respect, TGFI3 resembles the pituitary-derived and brain-derived fibroblast growth factors and a protein isolated from Buffalo rat liver, referred to as "differentiation inhibitor" or DI, each of which have been shown to inhibit myogenesis through a mechanism independent of cell proliferation (7, 13, 14, 35) . TGFI3 and the fibroblast growth factors are clearly distinct molecules; however, the relationship, if any, between TGFI3 and DI, remains to be determined.
TGF[3 did not affect the rate at which C-2 cells stopped dividing when switched into fusion-promoting medium. However, TGFI3 inhibited fusion and appearance of musclespecific gene products almost completely for at least 4 d, despite the fact that cells were in a quiescent state (Fig. 2) . Thus, simply prolonging G1 is not sufficient to induce differentiation. Previous studies have shown that myogenic differentiation occurs early in G1 and that cells arrested in late G1 fail to differentiate (4, 14) . Moreover, fibroblast growth factor causes transit of quiescent BC3HI cells to a restriction point 4-6 h into G1, that is nonpermissive for differentiation (14) . We do not know yet whether TGFI3 inhibits myogenesis by causing quiescent myoblasts to progress to this later region of G~. We also do not presently know whether TGFI3 directly represses transcription of muscle-specific genes or alternatively, leads to a generalized metabolic state that is incompatible with expression of this set of genes.
Removal of TGFI~ from quiescent undifferentiated C-2 or BC3HI cells, allowed the appearance of muscle-specific proteins at a normal rate with no apparent lag, which suggests that the inhibitory signals generated by TGFI3 are transient and require continuous occupancy of the TGFI3 receptor. After fusion, C-2 cells became refractory to the effects of TGFI3 while BC3H1 cells remained sensitive to TGFI3 independent of their state of differentiation. Whether the inability of TGFI3 to reverse the differentiation process in myotubes is due to a loss of TGFI3 receptors, as has been reported for EGF receptors during differentiation of mouse MMI4 myoblasts (16), or is due to some other alteration has not been determined.
In addition to inhibiting expression of creatine kinase and ACh receptor, TGFI3 also decreased the synthesis of at least 10 relatively abundant polypeptides in BC3HI cells (Fig. 6 ). The identifies of these proteins are currently unknown. However, they may represent other muscle-specific gene products that are subject to coordinate regulation by TGFI3. A set of polypepfides also was induced in BC3H1 cells by TGFI3. Recent studies by Leof et al. (15) suggest that at least some of these polypeptides may belong to the "competence" gene family, which is induced by platelet-derived growth factor during the transition of from quiescence to proliferation (3). Using AKR-2B cells, these investigators reported that TGFI3 caused induction of c-sis and the subsequent induction of c-fos, c-myc, and other PDGF-inducible gene products through an autocrine mechanism (15) . Identification of the polypepfides that are up and down regulated by TGFI3 in BC3H1 cells may help reveal the mechanisms through which this growth factor represses myogenic differentiation. Since many polypepfides are regulated by TGFI3 in BC3H1 cells, this will be an interesting system for studies on regulation of gene expression by this growth factor.
Little is known of the mechanisms involved in signal transduction by TGFI~. Tyrosine protein kinase activity, commonly associated with growth factor receptors, has not yet been demonstrated for the TGFI3 receptor, nor have other potential signaling mechanisms been identified. The similarities between the effects of TGFfl, fibroblast growth factor, and DI on myogenesis suggest that these growth factors may share a common postreceptor pathway. Currently, we are attempting to identify possible intracellular second messengers that may mediate the effects of TGFI3 and fibroblast growth factor on differentiation.
The physiological significance of TGFI3 as an inhibitor of myogenesis remains to be determined. TGFI3 might be involved in regulating the timing of myoblast fusion during early embryonic development. TGFI3 might also be responsible for maintenance of satellite cells, the mononucleated myoblasts that surround mature muscle fibers. Combined with previous studies, the results presented here suggest that TGFI3 plays an important role in regulation of tissue-specific gene expression during early development. It will be espe-cially interesting to determine whether TGFI3 interacts with common regulatory pathways in diverse cell types to control proliferation and differentiation.
